Sunbird Bio

Executive Summary

Sunbird Bio, a Cambridge-based diagnostics company focused on neurological disorders, announced in March 2026 its decision to wind down operations. Founded in 2018, the company aimed to advance diagnostic tools for conditions such as Alzheimer's disease and Parkinson's disease. Despite its innovative potential, Sunbird Bio has ceased all active development and is now in the process of closing. The company expressed gratitude to patients, investigators, employees, and partners who supported its mission. This decision marks the end of a promising venture in the neurodiagnostics space, leaving behind a legacy of scientific ambition but no commercial products or pipeline advancements.